Healthcare
Chimeric Therapeutics Limited (ASX:CHM)
Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology
Market Price : AUD 0.3150.005 (1.613%)
(as on 2021-10-24 00:05:19)
| Previous Close | Open | Close* | Day Range | 52 WEEK HIGH LOW |
|---|---|---|---|---|
| 0.31 | 0.315 | 0.315 | 0.305L 0.315 H | 0.24L 0.44 H |
| Last Trade | 0.315 |
|---|---|
| Change% | 1.6129 |
| 52 W H/L | 0.44/0.24 |
| EBITDA | 0 |
|---|---|
| NPAT After Abnormal Items | -15.114 M |
| Equity | 25.131 M |
| ROE% | -60.14% |
| Total Liabilities | 11.374 M |
|---|---|
| Total Revenue | 2,646 |
| Cash and Cash Equivalents | 22.41 M |
Stock Information
| Share price | 0.315 |
|---|---|
| Market Cap | 105.035 M |
| Price/Gross Cash Flow | -5.40 |
| Dividend Yield Excluding Special | 0.00% |
| Ending Shares | 196.833 M | 52-Week Range | 0.24-0.44 |
| P/E ratio | 0.000 |
|---|---|
| Sector P/E | -- | EPS | -8.00 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -571,190.89% |
| Gross Cash Flows Per Share | -0.06 |
| Net Gearing | -89.17% |
| Gross DPS (AUD) | 0 |
|---|---|
| Gross Dividend Yield (Annualized) | 0.00% |
| Earnings Yield | 0.000 |
| Net Tangible Asset (NTA) | 0.06 |
| Sales Per Share | 0.00 |
| Book Value Per Share | 0.13 |
Announcements
About Company
Chimeric Therapeutics Limited (ASX:CHM)
Clinical-stage oncology player Chimeric Therapeutics Limited (ASX:CHM) is developing revolutionary CAR-T cell therapies for the management of solid cancers. The Company’s CAR T cell therapy uses the chlorotoxin (CLTX) peptide as the chimeric antigen receptor (CAR) tumour recognition domain. Besides, Chimeric has established potent antitumor activity against the most challenging form of brain cancer known as glioblastoma (GBM).
The CLTX-CAR-T technology includes a novel CAR-T recognition domain, CLTX, that is derived from the poison of a scorpion. Currently, the Company is performing Phase 1 clinical studies in GBM at the City of Hope Cancer Centre in Los Angeles, California.
Chimeric Therapeutics is working to become a leader in cell therapy and develop life-transforming treatments. The Company believes that cellular therapies have the potential to cure cancer, and the Company will be able to bring the promise of cell therapy to life for more patients by combining their expertise in cell therapies with the world’s most innovative scientists.
Chimeric has licensed the exclusive global intellectual property (IP) rights for the CLTX CAR T cell therapy, currently under development for patients suffering from progressive and recurrent GBM.
CLTX CAR T cell therapy is also being investigated for the treatment of other solid tumours like colorectal cancer, melanoma, prostate cancer, and small cell lung cancer.
Chimeric’s CLTX CAR T therapy
The CLTX CAR T cell therapy is possibly a best-in-class therapy that has the potential to address the high unmet need of recurrent/progressive GBM patients. The study for developing the IP covering the CLTX CAR T cell therapy was performed at City of Hope.
CLTX CAR T cells have shown significant antitumor action against GBM in preclinical studies without exhibiting any off-tumour identification of normal human cells and tissues. The findings of preclinical studies reveal a potentially ideal safety and efficacy profile of the therapy.
Currently, Chimeric Therapeutics is actively engaged in developing its product pipeline with pioneering cell therapies to treat different types of cancer.
Corporate Information
|
|
|
|
Level 3, 62 Lygon Street, CARLTON SOUTH, VIC, AUSTRALIA, 3053
+61 3 98245254
Dividends
| Ex-Dividend Date | Franking | DPS (AUD) | Dividend Yield |
|---|---|---|---|
| 30/06/2021 | -- | 0.000 | 0.00% |
| 30/06/2020 | -- | 0.000 | -- |
Event Calendar
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Annual) | 2022-09-28 | 2022 |
| Report (Prelim) | 2022-08-30 | 2022 |
| Report (Interim) | 2022-02-25 | 2022 |
Financials
| Breakdown | 30/06/2021 | 30/06/2020 |
|---|---|---|
| Trading Revenue | 2,646 | -- |
| Other Revenue | 0 | 0 |
| Total Revenue | 2,646 | 0 |
| Interest Income | 0 | 0 |
| Interest Expenses | -5,877 | 0 |
| Expenses | -15.108 M | 0 |
| EBITDA | -15.105 M | 0 |
| Depreciation and Amortization | -2,633 | 0 |
| Depreciation | -2,633 | 0 |
| Amortisation | 0 | 0 |
| EBIT | -15.108 M | 0 |
| Pre Tax Profit | -15.114 M | 0 |
| Tax Expense | 0 | 0 |
| Net Profit After Tax | -15.114 M | 0 |
| Minority Interest | 0 | 0 |
| Preference Dividend | 0 | 0 |
| Net Abnormal Items | 0 | 0 |
| Reported Net Profit After Abnormal Items | -15.114 M | 0 |
| Ending Shares | 196.833 M | 330.526 M |
| Weighted Average Shares | 181.896 M | 330.526 M |
| EPS After Abnormal Items (cents) | -8.31 | 0 |
| Breakdown | 30/06/2021 | 30/06/2020 |
|---|---|---|
| Total Current Assets | 22.665 M | 36.381 M |
| Total Non Current Assets | 13.84 M | 15.186 M |
| Total Assets | 36.505 M | 51.567 M |
| Total Current Liabilities | 7.355 M | 16.253 M |
| Total Non Current Liabilities | 4.019 M | 0 |
| Total Liabilities | 11.374 M | 16.253 M |
| Net Assets | 25.131 M | 35.314 M |
| Breakdown | 30/06/2021 | 30/06/2020 |
|---|---|---|
| Net Operating Cash | -8.835 M | 0 |
| Net Invested Cash | -5.304 M | 0 |
| Net Financing Cash Flows | 36.541 M | 0 |
| Beginning Cash | 100 | 0 |
| End Cash Position | 22.41 M | 0 |
| Exchange Rate Adjustments | 8,503 | 0 |
| Other Cash Adjustments | 0 | 0 |
| Ending Cash | 22.41 M | 0 |
© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.